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Abbreviations 
ACS= acute coronary syndrome 
BID= bis in die 
BMS= bare-metal stent 
CABG= coronary artery bypass grafting 
CAD= coronary artery disease 
CI= confidence interval 
DAPT= dual antiplatelet treatment 
DCB= drug-coated balloons 
DES= drug-eluting stent   
ECG= electrocardiogram 
FFR= fractional flow reserve  
HR= hazard ratio 
ISR= in-stent restenosis 
IVUS= intravascular ultrasound 
LAD= left anterior descending artery  
LIMA= left internal mammary artery anastomosis 
MI= myocardial infarction 
OCT= optical coherence tomography 
OR= odds ratio 
PCI= percutaneous coronary interventions 
PROSPECT= Prospective Natural History Study of Coronary Atherosclerosis  
RR= risk ratio 
TLR= target lesion revascularization 
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Abstract 
Myocardial revascularization represents the most frequently performed therapeutic 
intervention worldwide. Current percutaneous and surgical revascularization 
techniques provide excellent short- and long-term clinical outcomes. However, despite 
the technological and procedural advances with the widespread use of drug-eluting 
stents and arterial bypass grafts in contemporary practice, a considerable proportion of 
patients require repeat revascularization procedures during long-term follow-up. The 
need for repeat revascularization has a major impact on patients quality of life and is 
associated with a significant economic burden. This Consensus Document summarizes 
the views on the management of myocardial revascularization failure of an expert panel 
of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The 
present document provides a broad and pragmatic overview of the clinical management 
of myocardial revascularization failure with a focus on the three key underlying 
mechanisms leading to repeat revascularization: 1) failure of percutaneous coronary 
interventions, 2) failure of coronary artery bypass grafting and 3) progression of 
coronary artery disease in native coronary segments previously untreated. The scope of 
the present position document is to provide a patient-oriented approach for the 
management of myocardial revascularization failure.  
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1. Introduction 
Myocardial revascularization represents the most frequently performed 
therapeutic intervention worldwide.[1,2] Current revascularization techniques provide 
excellent clinical outcomes during long-term follow-up.[1,3] Notwithstanding, 
approximately 20% of patients undergoing myocardial revascularization require a 
repeat revascularization procedure during the first 5 years of follow-up, with a higher 
risk after percutaneous coronary interventions (PCI) as compared with coronary artery 
bypass grafting (CABG).[4–7] The need for repeat revascularization has a significant 
impact on quality of life and health care resources, and exposes patients to risks 
intrinsically related to repeat hospitalizations and invasive procedures.[4,8,9] Moreover, 
patients requiring repeat revascularization are characterized by a high cardiac risk 
profile, due to comorbidities and anatomical features,[7][10] rendering their clinical 
management a relevant challenge in daily practice.  
This document summarizes the views on the management of myocardial 
revascularization failure of an expert panel of the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI). The committee members were proposed by the 
document chair and co-chair, and approved by the EAPCI Scientific Documents and 
Initiatives Committee.  
This document approaches the management of myocardial revascularization 
failure from a patient-oriented perspective, based on the underlying mechanisms 
leading to the clinical need for repeat revascularization: failure of PCI, failure of CABG, 
and progression of coronary artery disease (CAD) in native coronary segments 
previously untreated. The latter is not directly related to overt failure of a previous PCI 
or CABG. However, from a patient perspective, the need for a new revascularization 
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procedure represents a failure of the initial treatment strategy and should, therefore, 
be evaluated in the context of revascularization failure.  
This document has three key objectives: 1) To outline the different mechanisms 
underlying myocardial revascularization failure; 2) To detail the specific challenges to 
short- and long-term success of repeat revascularization procedures; 3) To delineate 
systematic and informed strategies aiming to increase the safety and efficacy of these 
procedures. 
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2. Failure of percutaneous coronary interventions  
 The vast majority of PCI procedures include stent implantation. Stent thrombosis 
and restenosis are key mechanisms of stent failure requiring repeat revascularization.  
 
2.1 Stent thrombosis  
Early stent thrombosis 
 Early stent thrombosis is defined as stent thrombosis occurring within the first 
30 days after stent implantation and is subclassified into acute (0-24 hours) and 
subacute (>24 hours–30 days) stent thrombosis.[11] Early stent thrombosis is a 
relatively infrequent occurrence in contemporary clinical practice (Table 1).[12] Most 
cases are related to mechanical or anatomical factors, in association with a 
thrombogenic milieu or an acute triggering event (Table 2).  
 
Late and very late stent thrombosis 
 Late stent thrombosis is defined as stent thrombosis that occurs between 30 
days and one year after stent implantation, while very late stent thrombosis is defined 
as stent thrombosis that occurs later than year after stent implantation.[13]  
 In contemporary large-scale drug-eluting stent (DES) trials, with broad inclusion 
criteria, stent thrombosis rates are low beyond 30 days after stent implantation (Table 
1). 
 Risk factors and underlying mechanisms of late and very late stent thrombosis 
are summarized in Table 2. 
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Management of patients with stent thrombosis  
 Most patients with stent thrombosis present with acute myocardial infarction 
(MI), with or without ST-segment elevation.[14] Accordingly, the principles of 
management are those recommended in relevant clinical practice guidelines.[15–17] 
Usually patients with suspected ST should undergo urgent coronary angiography to 
confirm the diagnosis and treat the underlying cause.  
Liberal use of intracoronary imaging [18] – with intravascular ultrasound or 
optical coherence tomography - is recommended by clinical practice guidelines, in order 
to detect and modify underlying mechanical factors, and to assess the contribution of 
concomitant restenosis or neoatherosclerosis to in-stent obstruction.[15]  
In case of a completely occluded vessel, flow should be restored initially, and 
intravascular imaging should be performed afterwards. In addition to intracoronary 
imaging, radiological stent enhancement is a helpful method to diagnose loss of stent 
integrity or under-expansion.[19] Although routine thrombus aspiration is not 
recommended by current guidelines, it might be considered in selected cases of stent 
thrombosis with a large thrombus burden. Similarly, glycoprotein IIb/IIIa receptor 
antagonists should be considered in view of the elevated pro-thrombotic milieu. 
Cangrelor use may be considered in patients not treated with a P2Y12 inhibitor at the 
time of stent thrombosis.  
Identified factors likely to have contributed to stent thrombosis should be 
corrected (Figure 1). Patients with deficits in mechanical stent integrity – such as stent 
gap, stent fracture or longitudinal deformation – as well as those with residual edge 
disease or dissection should generally be treated with repeat stenting. Stent crush or 
collapse is very rare but may be seen in heavily calcified lesions or at ostial locations and 
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also mandates repeat stenting. Significant stent under-expansion or malapposition 
should be corrected with non-compliant balloon dilation, including use of balloons with 
very high rated burst pressure as required. Intravascular lithotripsy may be considered 
for severe, otherwise non-dilatable stent under-expansion.[20] Following dilation of 
under-expanded stents, additional stent may be considered, although systematic repeat 
stenting in such cases should be avoided, especially if there are already multiple stent 
layers.  
 Non-mechanical causes of stent thrombosis may predominate in some cases. 
These include insufficient platelet inhibition due to hyporesponsiveness, non-
compliance to antiplatelet therapy, or interruption for unplanned or non-deferrable 
surgery. In the absence of clear identifiable mechanical causes of stent thrombosis, it 
may be sufficient to dilate the thrombosed stent to restore blood flow and administer 
antithrombotic agents (e.g. glycoprotein receptor inhibitors, intravenous P2Y12 
inhibitors). Subsequently, insufficient platelet inhibition must be evaluated. Use of 
point-of-care phenotypic and genetic testing have been suggested in patients with stent 
thrombosis without an evident underlying mechanical cause.[21,22] Assessment of dual 
antiplatelet treatment (DAPT) compliance is of paramount importance, especially within 
the first 30 days after PCI.[23] Prasugrel and ticagrelor are preferred over clopidogrel 
after an acute stent thrombosis.[15] Prolonged DAPT therapy beyond 12 months should 
be considered in patients after a stent thrombosis, weighting their increased thrombotic 
risk against their bleeding risk.[24–26] 
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Stent Thrombosis: What To Do 
Intracoronary imaging with IVUS and/or OCT to identify factors likely to have contributed to 
stent thrombosis 
PCI with DES in case of deficits in mechanical stent integrity (stent fracture or collapse)  
PCI with DES in case of residual edge disease or dissection 
High-pressure non-compliant balloon dilation in case of stent under-expansion or 
malapposition 
Assess adherence to antiplatelet therapy 
Assess platelet reactivity with point-of care assays in selected cases of acute stent 
thrombosis without a clearly identified mechanical cause 
After PCI for stent thrombosis, dual antiplatelet therapy with aspirin 75-100mg daily and 
prasugrel 10mg daily or ticagrelor 90mg BID for 12 months  
 
Stent Thrombosis: What NOT To Do 
Systematic repeat stenting in cases of stent under-expansion, especially in the presence of 
multiple stent layers 
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2.2 In-stent restenosis  
 In-stent restenosis (ISR) is a response to vessel wall injury that results in 
excessive tissue formation (i.e., neointimal hyperplasia or neoatherosclerosis) in stented 
segment. ISR is an angiographic diagnosis, defined as a diameter stenosis >50% within 
the stented segment (i.e. the stent and a 5 mm border proximal or distal to the stent). 
Although DES were highly effective in reducing the risk of ISR compared with bare-metal 
stent (BMS), ISR remains the most frequent cause of stent failure and the most common 
indication for target lesion revascularization (TLR). Large-scale clinical trials of patients 
treated with contemporary DES with broad inclusion criteria report rates of clinical 
restenosis (i.e. clinically indicated TLR) of <3% at 1-year and 10% at 5 years (Table 1). Of 
note, ISR presents as an acute coronary syndrome in up to 20% of cases.[27] 
 Clinical and angiographic factors predisposing to ISR are summarized in Table 2. 
 
Management of patients with in-stent restenosis  
Treatment of ISR is challenging compared with treatment of de novo lesions, 
owing to relatively high recurrence rates.[28] 
As the underlying substrate in ISR often overlaps with that of stent thrombosis, 
the principles of management are similar. However, while patients with thrombosis 
usually present with acute MI, patients with ISR may be asymptomatic and should only 
be treated in the presence of symptoms or objective evidence of ischemia. In stable 
settings, if revascularization is deemed necessary the strategy should be carefully 
planned. As is the case with native coronary artery stenoses, when ISR angiographic 
severity is unclear physiological guidance should be considered. If possible, the original 
lesion and the initial procedure (e.g., material used, maximum balloon pressures, 
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challenges encountered, etc.) should be reviewed to identify potential technical issues 
that may need to be addressed during the repeat intervention. Intracoronary imaging 
of restenotic lesions, with IVUS or OCT, may provide insights into the mechanisms 
underlying ISR (Table 2), by identifying contributing mechanical factors as well as 
characterizing the restenotic tissue type. Of note, in addition to intracoronary imaging, 
radiological stent enhancement is a helpful method to diagnose stent fracture or under-
expansion in patients with ISR.[19] 
 There are a number of technical issues that should be considered in the 
treatment of patients with ISR. Treatment should generally be focused on the stenosed 
segment rather than on the full length of the stented segment.[28] To prevent recurrent 
ISR, it is important to optimize the results of repeat procedures. Careful lesion 
preparation is required and mechanical issues should be recognized and corrected. 
Aggressive dilation of the underlying stent might be required especially in under-
expanded or collapsed stents, ideally using noncompliant balloons at high pressures 
(frequently >18 bar). Care should be taken to avoid geographic miss as this may lead to 
edge-related recurrence. Use of cutting balloons, or more flexible scoring balloons for 
lesion pre-dilation, reduces slippage of the balloon out of the stent (so called “water-
melon seeding”), which may lead to stent edge dissections, with the potential for 
subsequent “candy wrapper” patterns of stent edge-restenosis. These devices also 
incise the surface of the neointimal tissue, which theoretically may facilitate the uptake 
of drug delivery with drug-coated balloons (DCB) angioplasty or repeat DES 
implantation. Indeed, the ISAR-DESIRE-4 trial, showed improved angiographic outcomes 
after lesions pre-dilation with a scoring balloon compared with plain balloon angioplasty 
prior to DCB-angioplasty.[29] 
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 Occlusive ISR constitutes a challenging lesion subset for revascularization. While 
the use of a contemporary approach to chronic total occlusion recanalization is 
associated with improved procedural outcomes,[30] long-term results are worse than 
in de novo chronic total occlusion lesions, largely due to higher TLR rates.[31]  
 In the case of resistant stent under-expansion, very-high pressure (25 to 35 bar) 
balloons may be used. Modification of calcific plaques accounting for stent under-
expansion can be performed with excimer laser atherectomy [32] or intravascular 
lithotripsy, the latter also being useful in ISR with calcified neoatherosclerosis.[33] [34] 
Rotational atherectomy (also termed “rotastenting”) of undilatable under-expanded 
stents might be considered a second-line strategy and should be undertaken with 
caution due to the risk of serious complications.[35] Further study of the therapies 
discussed is required to confirm their potential benefits.  
 Following lesion preparation, a proportion of patients will require repeat 
stenting to correct loss of mechanical integrity of the underlying stent (e.g. due to 
fracture or gap or in rare cases, with demonstrated stent collapse). In the remaining 
patients, after dilatation and correction of any stent under-expansion, a number of 
treatment options are available, but there is general consensus that additional 
treatment beyond mechanical dilatation is required as outcomes after plain balloon 
angioplasty alone are poor.[36] The two most effective options are DCB-angioplasty or 
repeat stenting with DES.[37,38] European clinical practice guidelines recommend the 
use of DES or DCB as first-line therapy in patients with ISR (class I recommendation and 
level of evidence A for both).[15] Repeat stenting with DES seems to be marginally more 
effective in terms of angiographic recurrences and need for TLR as compared with DCB, 
particularly in patients with ISR of DES.[38,39] However, DCB avoids multiple metallic 
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layers on the vessel wall, which may be of particular concern in patients with recurrent 
ISR. Accordingly, selection between the two strategies may be considered based on the 
individual characteristics of the patient and lesion to be treated. For instance, DCB may 
be preferred over DES in ISR of BMS, multiple metal layers, or large side branches. 
Conversely, DES may be preferred over DCB in lesions with stent fracture, diffuse ISR 
extending beyond the stent edges, or in case of significant residual dissection or 
impaired flow after a balloon-only approach (Figure 2). Some operators prefer repeat 
stenting in the case of ISR at the stent edge though studies suggest that DCB appear to 
be equally effective for ISR confined to the body of the stent as for those mainly 
involving its edges.[40,41] 
 Antiplatelet treatment for patients undergoing PCI for ISR should not differ from 
that in patients with a de novo lesion. When ISR clinically presents as chronic coronary 
syndrome, switching antiplatelet therapy is not recommended unless 
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In-Stent Restenosis: What To Do 
Intracoronary imaging with IVUS and/or OCT to detect stent-related mechanical problems 
leading to ISR 
Aggressive pre-dilation of the underlying stent with non-compliant balloons at high 
pressure, especially in under-expanded or collapsed stents 
Lesion preparation with cutting balloons or scoring balloons in order to reduce balloon 
slippage outside the stent  
Very-high pressure balloons, intravascular lithotripsy, excimer laser or rotational 
atherectomy in case of resistant stent under-expansion 
After adequate lesion preparation, PCI with DES or DCB  
DES preferred for suboptimal predilation results (residual stenosis >50%, large* or flow-
limiting dissections), diffuse ISR, loss of mechanical integrity, and failed DCB-strategy  
DCB preferred for focal ISR, first ISR episode, ISR of BMS, and multiple metal layers 
CABG or a conservative strategy instead of a new PCI attempt in patients with recurrent 
episodes of diffuse ISR, after a Heart Team discussion 
After PCI for ACS due to underlying ISR, dual antiplatelet therapy with aspirin 75-100mg 
daily and prasugrel 10mg daily or ticagrelor 90mg BID for 12 months 
 
In-Stent Restenosis: What NOT To Do 
Treatment of the full length of the initial stent instead of focusing on the stenosed segment 
Plain balloon angioplasty-only strategy 
* Large dissection defined if: longitudinal extension >2mm, lateral extension >60º and 
involvement of medial or adventitia layers.[43] 
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 2.3. Acute functional failure after PCI 
Failing to identify hemodynamically significant coronary stenoses is one of the 
most common reasons portending to revascularization failure. Complementing 
coronary angiography with invasive functional assessment has received the highest level 
of recommendation by current guidelines to evaluate the hemodynamic relevance of 
intermediate-grade stenosis, when non-invasive evidence of ischemia is not 
available.[15] Myocardial revascularization aims to eliminate ischemia and is, therefore, 
expected to normalize findings of invasive functional assessment.  
While angiography is considered to be of limited ability to assess the 
hemodynamic relevance of coronary lesions, the adequacy of acute results after PCI is 
still mainly assessed based on angiographic visual estimation only. However, early 
evidence with fractional flow reserve (FFR) suggested that suboptimal FFR after stenting 
is an independent predictor of adverse clinical outcomes at 6 months.[44] More 
recently, a prospective observational study including 574 consecutive patients (664 
lesions) with FFR pre- and post-PCI evaluated clinical outcomes during a mean follow-
up of 31±16 months. Despite adequate angiographic result, 143 lesions (21%) had post-
PCI FFR values within the ischemic range (FFR ≤0.80).[45]  
A meta-analysis that synthesized evidence of 59 observational (prospective and 
retrospective) studies evaluating the relationship between post-PCI FFR and clinical 
outcomes found a normal distribution of post-PCI FFR values, with a mean of 0.90±0.04, 
and indicated that post-PCI FFR values appear to be related to the risk of repeat 
revascularization (OR 0.43, 95% CI 0.34-0.56) and major adverse cardiac events (0.71, 
95% CI 0.59-0.85) during follow-up.[46] A threshold of final FFR <0.90 has been proposed 
to define a suboptimal result after stenting.[47]  
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Several investigations showed that additional interventions may optimise the 
acute result in patients with suboptimal post-PCI FFR.[45,47,48] A recent prospective 
small-scale study suggested that intracoronary imaging with optical coherence 
tomography may reveal potentially treatable causes (i.e., stent underexpansion, 
incomplete lesion coverage, stent malaposition, edge dissection, or tissue protrusion), 
allowing optimisation of the post-PCI functional result.[47] However, whether additional 
interventions based on post-PCI functional assessment have a significant impact on 
clinical outcomes has not been clearly determined.[49] 
 
Acute Functional Failure: What To Do 
Repeat invasive functional assessment after stenting when already used to assess the 
hemodynamic relevance of the treated lesion 
Attempt to identify reasons for suboptimal (i.e., FFR <0.90) invasive functional assessment 
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3. Failure of coronary artery bypass grafting  
 Surgical graft failure is frequently observed with increasing time after CABG. 
Graft failure after use of saphenous vein grafts is as high as 50% at 10 years with vein 
graft occlusion rates of up to 27% within the first year after CABG.[50–52] Within the 
first month after surgery, the causes of graft failure are mostly related to the surgical 
technique and flow-pattern related thrombotic complications, while graft failure 
thereafter is characterized by neointimal hyperplasia and accelerated progression of 
CAD.[53–55] 
 
3.1 Acute graft failure (<1 month after surgery)  
 Acute graft failure can be due to graft dissection, kinking or twisting, anastomotic 
technical errors, impaired vessel run-off into the native coronary artery, competitive 
flow from the native coronary artery, or graft thrombosis. In a study of 366 patients with 
routine post-CABG angiography, 12.2% of the grafts were found to have relevant 
angiographic defects requiring a minor adjustment of the graft in 2.8%, an anastomosis 
revision in 3.4%, and intraoperative open-chest PCI in 6.0%.[53] Because of the logistic 
issues associated with routine direct postoperative angiography, intraoperative transit-
time flow measurements and high-frequency epicardial ultrasound have been used to 
detect causes of graft failure before chest closure and allow the opportunity for revision 
before myocardial ischemia occurs or progresses. 
When clinically relevant, acute graft failure may result in MI with a subsequent 
risk of mortality. The suspicion of early graft failure should arise in the presence of 
sudden clinical deterioration as indicated by ECG signs of ischemia, ventricular 
arrhythmias, biomarker changes, new wall motion abnormalities, or haemodynamic 
Disclaimer : As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been 
published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, 
and not that of the journal 
instability. Due to the low specificity of ECG changes and echocardiographic wall motion 
abnormalities during the postoperative course and the delay in appearance of 
biomarker changes, careful assessment of all variables will influence the decision making 
for angiographic evaluation.[15] 
Despite arterial grafting is recommended by current guidelines on myocardial 
revascularization [15], vein grafts continue to be used in larger numbers than arterial 
grafts, despite having lower long-term patency rates.[56] Arterial grafts tend to be 
reserved for the prognostically most important areas of myocardium (e.g., the left 
internal mammary artery anastomosis [LIMA] to the left anterior descending artery 
[LAD]). Acute arterial graft failure, therefore, typically has a more severe clinical 
presentation than vein graft failure, while the latter more often occurs subclinically. An 
observational study showed that acute graft failure of the LIMA-to-LAD anastomosis 
warranted reintervention in 80% of patients, while acute vein graft failure was treated 
conservatively in approximately 50% of patients.[57] 
 
Management of acute graft failure 
 Angiographic assessment is recommended if there is a suspicion of acute graft 
failure early postoperatively, and is performed in about 1-5% of patients.[58–61] In a 
recent meta-analysis of 9 studies and 1,104 patients with suspected perioperative MI 
after CABG, acute graft failure was diagnosed in 62.1% of patients.[62] Incomplete 
revascularization was the cause of the MI in 6.1% of patients, and 3.5% of patients had 
a native coronary artery culprit. Remarkably, in 31.6% of patients no cause of 
perioperative MI could be identified. In this context, it is important to underscore that 
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haziness at the anastomosis in this acute period may be difficult to interpret and may 
not be related to the clinical problem. 
The treatment strategy for acute graft failure should be made in an ad hoc Heart 
Team meeting. As summarized in Figure 3, a number of parameters should be 
considered in the decision-making process such as technical reason for acute failure (i.e., 
problems related with the suture), age and risk profile of the patient, the patient’s 
clinical condition (e.g., haemodynamic status and inotropic support), pre-CABG native 
vessel CAD and coronary anatomy, extent and timing of ischemia, graft configuration, 
and extent of myocardium at risk.  
In the setting of acute graft failure, emergency PCI may limit the extent of 
infarction. Current clinical guidelines advocate that PCI should be the preferred strategy 
in cases of acute graft failure where the anatomy is suitable.[15] In such cases, the target 
for PCI should be the native vessel or the internal mammary artery (IMA) graft, while an 
acutely occluded vein graft and any anastomotic site should be avoided, if possible, due 
to concerns regarding fragility of the new anastomosis as well as the risk of embolisation 
and perforation. The impact of in-hospital PCI following CABG was investigated in a 
retrospective study in which patients with acute coronary ischemia requiring PCI after 
CABG (N=14,323) were compared with those who did not undergo PCI (N=540,664). 
Post-CABG PCI was associated with an increased risk of unadjusted in-hospital mortality 
(5.1% vs. 2.7%; p < 0.001), higher rates of stroke (2.1% vs. 1.6%; p < 0.001), acute kidney 
injury (16% vs. 12.3%; p < 0.001), and a 50% cost increase.[63] 
Redo CABG should be preferred when the anatomy is unsuitable for PCI, when 
an anastomotic error is evident, or when several important grafts are occluded.[15] 
Conservative treatment should be considered in cases where diagnosis has been 
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delayed and viability is expected to be limited. In asymptomatic patients, repeat 
revascularisation should be considered if the failed graft supplies a large territory of 
myocardium. 
 
Acute Graft Failure: What To Do 
Coronary angiography after CABG in patients with sudden clinical deterioration indicated 
by: 
- symptoms of ischemia and/or abnormal biomarkers suggestive of perioperative MI 
- ischemic ECG changes indicating large area of myocardium at risk 
-  new significant wall motion abnormalities 
- haemodynamic instability. 
Emergency redo-CABG or PCI decided upon by ad-hoc consultation in the Heart Team, 
based on the feasibility of revascularization, area at risk, comorbidities, and clinical status 
PCI of the native vessel rather than PCI of the graft 
Conservative treatment in graft failure cases where diagnosis has been delayed and viability 
is expected to be limited 
In asymptomatic patients, repeat revascularisation if the failed graft supplies a large 
territory of myocardium 
 
Acute Graft Failure: What NOT To Do 
PCI in case of unsuitable anatomy, anastomotic error of the LIMA to LAD or at the Y-
anastomosis of a composite arterial graft 
 
 
3.2 Late graft failure (>1 month after CABG) 
 As the time from surgery increases, vein grafts become prone to a process of 
aggressive and accelerated atherosclerosis. This results in mostly diffuse soft lipid-rich 
atherosclerotic plaques with extensive necrotic cores with or without intraplaque 
haemorrhage prone to rupture and downstream embolization.[54][64]  
 Clinically relevant late graft failure presents mostly in form of stable or unstable 
angina pectoris.[65–68]  
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Management of late graft failure 
 A number of critical issues should be considered when treating patients with 
degenerated grafts, including whether to perform redo CABG or PCI, whether to treat 
native arteries or degenerated grafts, and the risk of distal embolization in case of graft 
intervention. 
PCI is considered treatment of choice in case of late graft failure. Randomized 
comparisons between redo CABG and PCI, however, are lacking partly due to patients’ 
unwillingness to be allocated to redo CABG.[69] In a subgroup analysis of patients with 
late graft failure from the AWESOME trial and registry, redo CABG surgery was 
associated with higher peri-procedural mortality as compared with PCI.[69] Therefore, 
redo CABG surgery is recommended only in case of extensive native CAD with multiple 
graft occlusion, particularly in the absence of patent arterial grafts.[15] 
 PCI of vein grafts is considered a high-risk intervention due to an increased risk 
of slow/no-reflow related to distal embolization of the friable atheroma, depending on 
the degree of graft degeneration.[70,71] Embolic protection devices have been 
proposed to prevent distal embolization.[72,73] A randomized trial performed in early 
2000 showed a significant benefit of embolic protection devices in PCI of vein grafts [72] 
and a similar trend was seen in a subsequent randomized trial that was underpowered 
due to premature termination [73]. However, a meta-analysis of 52.893 patients 
enrolled in these randomized trials and in more recent observational studies did not 
suggest a benefit of routine use of embolic protection devices in PCI of vein grafts.[74]  
 Several randomized trials have compared DES with BMS in vein graft lesions.[68] 
In a meta-analysis of randomized evidence, no differences between DES and BMS was 
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observed in terms of all-cause death (RR 1.06, 95% CI 0.76-1.48), MI (RR 0.81, 95% CI 
0.50-1.29), target vessel revascularization (RR 0.73, 95% CI 0.48-1.11) and target lesion 
revascularization (RR 1.05, 95% CI 0.76-1.43) at longest follow-up.[68] In the ISAR-CABG 
trial, DES use was associated with a significantly lower risk of target-lesion 
revascularization during the first year of follow-up (HR 0.49, 95%CI 0.28-0.86) which was 
offset by a higher risk between 1 and 5 years (HR 2.10, 95% CI 1.37-3.22) as compared 
to BMS, with a significant interaction between treatment effect and time (pinteraction 
<0.001) .[66,67] 
 PCI of vein grafts is associated with a higher risk of adverse events as compared 
to PCI of native coronary arteries among patients with late graft failure.[75] In a registry 
of 11,118 veterans, PCI of vein grafts was associated with significantly higher risk of 
mortality (adjusted hazard ratio 1.30, 95% CI 1.18-1.42), MI (adjusted HR 1.61, 95% CI 
1.43-1.82) and repeat revascularization (adjusted HR 1.69, 95% CI 1.50-1.71) as 
compared to PCI of native arteries during a median follow-up of 3 years.[75]  
Although available evidence clearly supports PCI of the native artery in case of 
late graft failure, anatomical complexities – such as multiple chronic total occlusions of 
native arteries – might limit the success of such strategy, forcing interventionalists to 
treat degenerated grafts instead. Despite improvements in recanalization techniques 
and available dedicated tools, previous CABG surgery remains one of the most 
important predictors of PCI failure in chronic total occlusions.[76] Therefore, the 
decision to treat native artery lesions or surgical grafts depends on CAD anatomical 
complexity and the interventionalists expertise in complex PCI, seeking the most 
complete revascularization. The decision should be made on an individual patient basis, 
giving priority to PCI of native arteries.  
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Late Graft Failure: What To Do 
PCI as first choice over redo-CABG for late graft failure 
PCI of the native vessel rather than PCI of the graft 
PCI strategy based on operator experience in complex PCI 
Distal protection devices for PCI of vein graft lesions with diffused degeneration 
IMA for redo-CABG in patients in whom the IMA was not used previously 
Redo-CABG in patients without a patent IMA graft to the LAD, after checking its patency 
Redo-CABG in case of extensive native CAD, anatomically unsuitable for PCI, in absence of 
patent grafts (especially arterial) 
 
Late Graft Failure: What NOT To Do 
Routine use of embolic protection devices for PCI of vein grafts  
Plain balloon-only for PCI of the graft 
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4. Repeat revascularization due to progression of CAD  
 CAD progression in native coronary segments previously untreated is the 
primary cause of repeat procedures after myocardial revascularization.  
 
Native CAD progression after PCI 
 Disease progression is responsible for a relevant proportion of repeat 
revascularization procedures after PCI,[6] although the incidence varies based on the 
clinical and anatomic characteristics of the population studied. The Prospective Natural 
History Study of Coronary Atherosclerosis (PROSPECT) study studied the relative 
contribution of events related to the initially treated lesion (culprit lesion) and events 
related to CAD progression in non-culprit sites among 697 patients with ACS undergoing 
PCI.[77] The cumulative rate of major adverse cardiac events – a composite of cardiac 
death, arrest, MI, and hospitalization for angina – was 20.4% at 3 years, with 12.9% 
events related to the culprit lesion and 11.6% events due to CAD progression at non-
culprit sites. Overall, 65% of all events occurred within 1 year after PCI, with a relatively 
equal distribution between events related to the culprit lesion and those related to CAD 
progression. The overall repeat revascularization rate was 17.1% at 3 years, with an 
equal contribution of events related to the culprit lesion and those related to CAD 
progression. 
 Predictors of CAD progression in previously untreated native coronary segments 
include clinical and angiographic factors that are largely overlapping with predictors of 
PCI and CABG failure, such as age, diabetes mellitus, complex coronary anatomy, extent 
of CAD, small vessel CAD, and previous PCI of vein grafts or ostial lesions.[6][78]  
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Native CAD progression after CABG 
 Current recommendations for CABG inherently select patients at higher risk for 
native CAD progression. These include patients with multi-vessel CAD, high anatomical 
complexity and extent of CAD, and coexistence of multiple comorbidities including 
diabetes mellitus, reduced left ventricular ejection fraction, and chronic kidney disease. 
Historical evidence indicates that accelerated CAD progression occurs up to 10-fold 
more frequently in non-obstructive atherosclerotic lesions in bypassed coronary arteries 
compared with similar lesions in non-bypassed vessels at 3 years after CABG.[79] In 
another study, the risk of CAD progression was twice as high in arteries with patent 
grafts as compared to those with closed grafts, with the majority of grafted arteries with 
CAD progression being completely occluded. A more recent analysis of contemporary 
surgical techniques showed similar results, with development of a new chronic total 
occlusion in a native coronary artery in >40% of patients within 1 year after CABG, 
strongly predicted by a severe (>90%) proximal stenosis in the same vessel.[80] 
 
General principles for management of CAD progression 
 In case of CAD progression in previously untreated native coronary segments 
following revascularization, treatment recommendations should be based on symptoms 
and evidence of myocardial ischemia. In this context, optimal medical therapy plays a 
pivotal role not only to reduce the risk of CAD progression but also for an initial 
management of patients with evidence of CAD progression. We refer to relevant clinical 
practice guidelines for a comprehensive assessment on recommendations for optimal 
medical management, which represents the cornerstone for prevention and treatment 
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of CAD progression.[15,81,82] The interventional management of CAD progression 
differs according to the initial revascularization modality. 
 
Management of CAD progression after PCI 
 In contemporary large-scale PCI trials, up to one-third of patients enrolled were 
previously treated with PCI.[83–85] Percutaneous treatment of CAD progression after a 
previous PCI is generally reasonable. A surgical revascularization strategy may be 
appropriate in case of CAD progression involving proximal segments of major coronary 
arteries or multivessel disease involving the left main or proximal LAD. A large registry 
that evaluated outcomes of patients with previous PCI undergoing CABG showed that 
early mortality and adverse ischemic events did not significantly increase in patients 
with single or multiple previous PCI procedures.[86] Therefore, a strategy based on 
clinical and anatomical factors similar to patients with a first diagnosis of CAD is 
recommended in patients with CAD progression after PCI (Figure 4). 
 
Management of CAD progression after CABG 
 Repeat revascularization procedures after CABG are typically performed in older 
patients with more comorbidities and more complex coronary anatomy as compared to 
patients with a first diagnosis of CAD. Furthermore, in these patients arterial conduits 
tend to be less frequently available, having already been used.[87] Therefore, re-do 
CABG is associated with increased procedural risks and worse clinical outcomes 
compared with a first CABG. Recent evidence indicates a trend towards a decreased risk 
of adverse events in patients treated with PCI coupled with an increase in PCI use in this 
setting.[70][88] In view of the paucity of available comparative effectiveness evidence, 
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in these patients the selection of the repeat revascularization strategy should be based 
on the assessment of clinical and anatomical risk profiles on an individual patient basis 
in discussion within the Heart Team (Figure 3, Figure 4).[89][69]    
 
CAD Progression: What To Do 
Repeat revascularization in patients with evidence of CAD progression and with a large area 
of ischemia or severe symptoms despite medical therapy  
Base the selection of the repeat revascularization strategy on the assessment of clinical and 
anatomical risk profiles on an individual basis in the context of the Heart Team 
If considered safe, PCI with DES as first choice over CABG  
IMA for redo-CABG in patients in whom the IMA was not used previously 
Redo-CABG in patients without a patent IMA graft to the LAD 
 
CAD Progression: What NOT To Do 
Routine Invasive angiography tests in asymptomatic patients with prior revascularization 
Routine ad-hoc PCI in patients with progression of CAD after CABG 
 
Conclusions 
Current percutaneous and surgical revascularization techniques are associated with 
excellent procedural and long-term clinical outcomes. However, a considerable 
proportion of patients require repeat revascularization procedures during long-term 
follow-up due to failure of the initial revascularization – either PCI or CABG – or 
progression of disease in previously untreated coronary segments. This document 
provides an evidence-based guidance for the management of myocardial 
revascularization failure based on the underlying mechanism, the timing and the clinical 
and angiographic characteristics of individual patients. 
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Figure 1. Algorithm for the management of stent thrombosis.  
PCI=percutaneous coronary interventions, DES=drug-eluting stent. *Avoiding stent implantation 
should be considered in cases with severe under-expansion or malapposition without further 
underlying mechanisms. In patients with stent thrombosis due to severe neointimal hyperplasia 
or neoatherosclerosis PCI with DEB might be considered. Images were kindly provided by Drs 
Nicolas Amabile, Fernando Alfonso and Gennaro Sardella. 
 
Figure 2. Algorithm for the management of in-stent restenosis  
BMS=bare-metal stent; DCB=drug-coated balloon. DES=drug-eluting stent; ISR=in-stent 
restenosis; NC=non-compliant; PCI=percutaneous coronary intervention. *In patients with 
edge dissection or acute recoil after lesion predilation, PCI with DES should be considered. 
Images were kindly provided by Drs Nicolas Amabile, Fernando Alfonso and Gennaro Sardella. 
 
Figure 3. Algorithm for the management of patients with surgical graft failure. 
CTO= chronic total occlusion; DAPT= dual antiplatelet therapy; LAD= left anterior descending 
artery; LIMA= left internal mammary artery; PCI= percutaneous coronary intervention; 
SGF=surgical graft failure 
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Figure 4. Factors that may guide revascularization strategy for CAD progression. 
CAD= coronary artery disease; COPD= chronic obstructive pulmonary disease; DAPT= dual 
antiplatelet therapy; STS = Society of Thoracic Surgery Risk Score 
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Table 1. Rates of stent thrombosis and TLR in selected contemporary large-scale all-comer clinical trials[90,91,100–107,92–99]  
 
 RESOLUTE All comers DUTCH PEERS CENTURY II BIOSCIENCE BIO-RESORT SORT OUT VII BIONICS BIONYX SORT OUT VIII 
 Resolute Xience Resolute Promus Ultimaster Xience Orsiro Xience Synergy Resolute Orsiro Orsiro Nobiro BioNIR Resolute Resolute Orsiro BioMatrix Synergy 
Definite ST 
30 
days       0.3% 0.2%          0.4% 0.7% 
1 
year 1.2% 0.3% 0.3% 0.6% 0.9%* 0.9%* 0.9% 0.4% 0.3% 0.2% 0.3% 0.4% 1.2% 0.4% 0.5% 0.1% 0.5% 0.9% 0.7% 
2 
years   0.8% 0.9%   1.0% 0.7% 0.6% 0.5% 0.4% 0.8% 1.4%       
3 
years         0.7% 0.5% 0.7%         
5 
years 1.6% 0.8% 1.1% 1.1% 1.3% 1.1% 1.5% 1.5%            
Definite or Probable ST 
30 
days 1.1% 0.5%     1.8% 2.2%            
1 
year 1.7% 0.7% 0.5% 0.8%   2.8% 3.4% 0.4% 0.5% 0.4% 0.9% 1.6% 0.4% 0.6% 0.1% 0.7% 1.4% 1.1% 
2 
years 1.9% 0.9% 1.1% 1.1%   3.7% 4.7% 0.9% 0.7% 0.6% 1.3% 1.8%       
3 
years         1.0% 0.8% 1.0%         
5 
years 2.4% 1.7% 1.5% 1.3% 1.3% 1.3% 5.8% 7.2%            
TLR 
30 
days                    
1 
year   2.2% 2.2% 2.2%* 1.6%* 4.0% 3.1% 1.4% 1.4% 1.5% 2.0% 2.9% 3.2% 2.3% 2.5% 1.9% 2.5% 2.3% 
2 
years 5.7% 5.1% 3.8% 3.5%   5.5% 4.8% 2.3% 2.9% 2.1% 3.6% 4.5%       
3 
years         3.1% 3.6% 2.8%         
5 
years 10.2% 8.9%   9.4% 8.2% 10.3% 10.0%            
 
ST=stent thrombosis, TLR=target lesion revascularization. *9 months follow-up. 
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Table 2. Risk factors and underlying mechanism of stent thrombosis and in-stent restenosis 
 
 Stent Thrombosis[12,14,18,108–113] In-Stent Restenosis[111,114–117] 
 Early Late Very late  
Risk factors     
Patient-related 
- Acute clinical presentation 
- Poor response to antiplatelet 
treatment 
- High on-treatment platelet 
reactivity 
- Current smoking 
- Genetic variants* 
- Diabetes mellitus 
- LVEF <40% 
 
- Current smoking 
- Multivessel disease 
- Younger age 
- LVEF <40% 
- eGFR<30 ml/(min·m2) 
- Current smoking 
- Multivessel disease 
- Younger age 
- Diabetes mellitus 
- Prior bypass surgery 
Lesion-related 
- LMCA or LAD lesion 
- Residual dissection 
- TIMI flow grade <3 
- Bifurcation lesion 
- Type C lesions 
- Severe calcified lesions 
- LAD lesion 
- Bypass graft lesion 
- Presence of thrombus 
- Bifurcation lesion 
- Severe calcified lesions 
- LAD lesion 
- Bypass graft lesion 
- Presence of thrombus 
 
- Small vessel size 
- Complex morphology 
- Previous diffuse ISR 
- Bifurcation lesion 
Stent-related - Under-sizing - Overlapping stents 
- Long stent length 
- Overlapping stents 
- Long stent length 
- Overlapping stents - Long stent length 
Underlying mechanisms 
- Uncovered struts 
- Stent under-expansion 
- Malapposition 
- Uncovered struts 
- Malapposition 
- Neoatherosclerosis 
- Uncovered struts 
- Malapposition 
- Neointimal hyperplasia 
- Neoatherosclerosis 
- Stent under-expansion 
- Loss of mechanical integrity 
eGFR= estimated glomerular filtration rate, ISR=in-stent restenosis, LAD=left anterior descending artery, LMCA= left main coronary artery, LVEF= left ventricular ejection 
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